Department of Pharmaceutical Sciences, Via Luigi Mangiagalli 25, 20133 Milano, Italy.
Department of Biotechnology, Chemistry and Pharmacy - DoE 2018-2022, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Bioorg Chem. 2021 Mar;108:104657. doi: 10.1016/j.bioorg.2021.104657. Epub 2021 Jan 27.
Wound healing represents an urgent need from the clinical point of view. Several diseases result in wound conditions which are difficult to treat, such as in the case of diabetic foot ulcer. Starting from there, the medicinal research has focused on various targets over the years, including GPCRs as new wound healing drug targets. In line with this, GPR120, known to be an attractive target in type 2 diabetes drug discovery, was studied to finalize the development of new wound healing agents. Pinocembrin (HW0) was evaluated as a suitable compound for interacting with GPR120, and was hybridized with fatty acids, which are known endogenous GPR120 ligands, to enhance the wound healing potential and GPR120 interactions. HW0 and its 7-linolenoyl derivative (HW3) were found to be innovative wound healing agents. Immunofluorescence and functional assays suggested that their activity was mediated by GPR120, and docking simulations showed that the compounds could share the same pocket occupied by the known GPR120 agonist, TUG-891.
创伤愈合是临床急需解决的问题。一些疾病导致的伤口难以治疗,例如糖尿病足溃疡。从那时起,多年来药物研究集中在多个靶点上,包括 G 蛋白偶联受体 (GPCR) 作为新型创伤愈合药物靶点。与这一目标一致,GPR120 作为 2 型糖尿病药物发现的一个有吸引力的靶点,其最终开发了新型创伤愈合剂。基于 Pinocembrin (HW0) 与 GPR120 相互作用的研究,将其与脂肪酸(已知的内源性 GPR120 配体)进行杂交,以增强创伤愈合潜力和 GPR120 相互作用。HW0 和其 7-亚麻酰基衍生物 (HW3) 被发现是创新的创伤愈合剂。免疫荧光和功能测定表明其活性是通过 GPR120 介导的,对接模拟表明,这些化合物可以共享与已知 GPR120 激动剂 TUG-891 相同的结合口袋。